NCT06655090 Fibrotic Interstitial Lung Disease Early Recognition and Strategic Therapy Study in China
| NCT ID | NCT06655090 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Dai Huaping |
| Condition | Interstitial Lung Disease (ILD) |
| Study Type | OBSERVATIONAL |
| Enrollment | 10,000 participants |
| Start Date | 2021-12-01 |
| Primary Completion | 2024-11-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 10,000 participants in total. It began in 2021-12-01 with a primary completion date of 2024-11-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This project aimed to: 1) construct a cohort of no less than 10000 cases of f-ILD (including pneumoconiosis ≥3000 cases) with continuous regular follow-up to reveal the clinical phenotypes closely related to the development, progression and prognosis of pulmonary fibrosis; 2) systematically evaluate the safety and effectiveness of frozen lung biopsy, surgical lung biopsy/thoracoscopic lung biopsy and other techniques, and to optimize the histological diagnosis method of f-ILD; 3) construct a set of artificial intelligence (AI) evaluation system for quantitative evaluation of pulmonary fibrosis and its severity, and develop application software; 4) excavate and verify important molecular targets for the formation of pulmonary fibrosis and identify biomarkers; 5) combined with clinical phenotype, imaging, pathology and biomarkers to establish f-ILD early recognition and progress model, intervention strategies, guidelines and consensus, and applicated nationwide.
Eligibility Criteria
Inclusion Criteria: * Diagnosed as ILD Exclusion Criteria: * Lack of chest CT * Patients refused to participant
Contact & Investigator
Huaping Dai, M.D. Ph.D.
STUDY DIRECTOR
China-Japan Friendship Hospital
Frequently Asked Questions
Who can join the NCT06655090 clinical trial?
This trial is open to participants of all sexes, studying Interstitial Lung Disease (ILD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06655090 currently recruiting?
Yes, NCT06655090 is actively recruiting participants. Contact the research team at daihuaping@sina.com for enrollment information.
Where is the NCT06655090 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT06655090 clinical trial?
NCT06655090 is sponsored by Dai Huaping. The principal investigator is Huaping Dai, M.D. Ph.D. at China-Japan Friendship Hospital. The trial plans to enroll 10,000 participants.